Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.

Article  CAS  PubMed  Google Scholar 

Siegel RL, et al. Cancer statistics, 2023. CA: A Cancer J Clin. 2023;73(1):17–48.

Google Scholar 

Al-Share B, Hammad N, Diab M. Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy. Cancer Metastasis Rev. 2021;40(1):355–71.

Article  PubMed  Google Scholar 

Dhillon S. Adagrasib: First Approval. Drugs. 2023;83(3):275–85.

Article  CAS  PubMed  Google Scholar 

Nakajima EC, et al. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kemp SB, et al. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Cancer Discov. 2023;13(2):298–311.

Article  CAS  PubMed  Google Scholar 

Pishvaian MJ, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020;21(4):508–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philip PA, et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin Cancer Res. 2022;28(12):2704–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salem ME, et al. Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases. J Clin Oncol. 2016;34(15_suppl):4121–4121.

Article  Google Scholar 

Lee MS, Pant S. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. Am Soc Clin Oncol Educ Book. 2021;41:1–13.

PubMed  Google Scholar 

Singh H, et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. Clin Cancer Res. 2023;29(22):4627–43. https://doi.org/10.1158/1078-0432.CCR-22-3930.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desai A, et al. KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities. J Clin Oncol. 2022;40(16_suppl):4130–4130.

Article  Google Scholar 

Luchini C, et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39(1):227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philip PA, et al. Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC). J Clin Oncol. 2020;38(15_suppl):4629–4629.

Article  Google Scholar 

Singhi AD, et al. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019;156(8):2242-2253.e4.

Article  CAS  PubMed  Google Scholar 

Hendifar A, et al. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021;5:1325–38.

Article  Google Scholar 

Ardalan B, et al. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report. Cold Spring Harb Mol Case Stud. 2021;7(5):a006108.

Article  PubMed  PubMed Central  Google Scholar 

Komatsu H, et al. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS ONE. 2014;9(2):e87875.

Article  PubMed  PubMed Central  Google Scholar 

Ritterhouse LL, et al. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Mod Pathol. 2017;30(12):1720–7.

Article  CAS  PubMed  Google Scholar 

Patra KC, et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018;20(7):811–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramakrishnan G, et al. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Cell Rep. 2022;41(6):111623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1–10.

Article  CAS  PubMed  Google Scholar 

O’Reilly EM, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(10):1431–8.

Article  PubMed  PubMed Central  Google Scholar 

Golan T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Javle M, et al. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021;7(5):693–9.

Article  PubMed  PubMed Central  Google Scholar 

Reiss KA, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol. 2022;23(8):1009–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heining C, et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov. 2018;8(9):1087–95.

Article  CAS  PubMed  Google Scholar 

Fernandez-Cuesta L, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4(4):415–22.

Article  CAS  PubMed  Google Scholar 

Jonna S, et al. Detection of NRG1 Gene Fusions in Solid Tumors. Clin Cancer Res. 2019;25(16):4966–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Safran H, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004;22(5):706–12.

Article  CAS  PubMed  Google Scholar 

Safran H, et al. Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. Am J Clin Oncol. 2011;34(1):50–2.

Article  CAS  PubMed